p53 protein in pediatric malignant astrocytomas: A study of 21 patients

Journal of Neuro-Oncology

Volumn 32, Issue 3, 1997, Pages 225-233

  Bhattacharjee, Meena B ^a   Bruner, Janet M ^b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Immunohistochemistry; Mutation analysis; p53 protein; Pediatric malignant astrocytomas

Indexed keywords

PROTEIN P53;

ADOLESCENT; ANAPLASTIC CARCINOMA; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GENETICS; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; INFANT; MALE; MOLECULAR BIOLOGY; NEWBORN;

ADOLESCENT; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GENES, P53; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; MALE; MUTATION; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031040125     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005727902387     Document Type: Article

References (43)

1. Young JL, Ries LG, Silverberg E, Horm JW, Miller RW: Cancer incidence, survival and mortality for children younger than age 15 years. Cancer 58: 598-602, 1986
2. Menkes JH (ed) In: Textbook of Child Neurology, 3rd ed, Lea and Febiger, Philadelphia, p. 531, 1985
3. Balestrini MR, Zanette M, Micheli R, Fornari M, Solero CL, Broggi G: Hemispheric cerebral tumors in children. Long-term prognosis concerning survival rate and quality of life - considerations on a series of 64 cases operated upon. Childs Nerv Syst 6: 143-147, 1990
4. Marchese MJ, Chang CH: Malignant astrocytic gliomas in children. Cancer 65: 2771-2778, 1990
5. Nishio Sh, Takeshita I, Fujii K, Fukui M: Supratentorial astrocytic tumors of childhood: a clinicopathologic study of 41 cases. Acta Neurochir (Wien) 101: 3-8, 1989
6. Louis DN, Rubio M-P, Correa KM, Gusella JF, Von Deimling A: Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens. J Neuropath Exp Neurol 52: 507-515, 1993
7. Ahmed Rasheed BK, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD, Bigner SH: Alterations of the TP53 gene in human gliomas. Cancer Res 54: 1324-1330, 1994
8. Wong AJ, Zoltick PW, Moscatello DK: The molecular biology and molecular genetics of astrocytic neoplasms. Sem Oncol 21 (2): 139-148, 1994
9. Batra SK, Ahmed Rasheed BK, Bigner SH, Bigner DD: Biology of Disease - Oncogenes and anti-oncogenes in human central nervous system tumors. Lab Invest 71 (5): 621-637, 1994
10. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin. Nature 313: 144-147, 1985
11. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B: Increased expression of the EGFR gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84: 6899-6903, 1987
12. Fuller GN, Bigner SH: Amplified cellular oncogenes in neoplasms of the human central nervous system. Mut Res 276: 299-306, 1992
13. Von Deimling A, Louis DN, Von Ammon K, Petersen I, Hoell T, Chung RY, Martuza RL, Schoenfeld DA, Yasargil MG, Wiestler OD, Seizinger BR: Association of epidermal growth factor receptor gene amplification with loss of chromsome 10 in human glioblastoma multiforme. J Neurosurg 77: 295-301, 1992
14. Bigner SH, Vogelstein B: Cytogenetics and molecular genetics of malignant gliomas and medulloblastomas. Brain Pathol 1: 12-18, 1990
15. Fults D, Pedone CA, Thomas GA, White R: Allelotype of human malignant astrocytoma. Cancer Res 50: 5784-5789, 1990
16. Chung RY, Whaley J, Kley N, Anderson K, Louis DN, Menon A, Hettlich C, Freiman R, Hedley-Whyte ET, Martuza R, Jenkins R, Yandell D, Seizinger BR: p53 gene mutation and chromosome 17p deletion in human astrocytomas. Genes Chromosom Cancer 3: 323-331, 1991
17. Von Deimling A, Eibl RH, Ohgaki H, Louis DN, Von Ammon K, Petersen I: p53 mutations are associated with 17p allelic loss in grade II and III astrocytoma. Cancer Res 52: 2987-2990, 1992b
18. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B: Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708, 1989
19. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991
20. Finlay CA, Hinds PW, Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 57: 1083-1093, 1989
21. Sidransky D, Mikkelson T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature 355: 846-847, 1992
22. Von Deimling A, Von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3: 19-26, 1993
23. Lang FF, Miller DC, Koslow M, Newcomb EW: Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 81: 427-436, 1994
24. Newcomb EW, Madonia WH, Pisharody S, Lang FF, Koslow M, Miller DC: A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol 3: 229-235, 1993
25. Louis DN, Von Deimling A, Chung RY, Rubio M-P, Whaley JM, Eibl RH, Ohgaki H, Wiestler OD, Thor AD, Seizinger BR: Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 52: 31-38, 1993
26. Bruner J, Saya H, Moser R: Immunocytochemical detection of p53 in human gliomas. Mod Pathol 4: 671-674, 1991
27. Harris C, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. New Engl J Med 329: 1318-1327, 1993
28. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, Mendelow AD, Sengupta RP, Pearson ADJ: Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labeling in brain tumors. Br J Cancer 66: 373-385, 1992
29. Iuzzolino P, Ghimenton C, Nicolato A, Giorgiutti F, Fina P, Doglioni C, Barbareschi M: p53 protein in low grade astrocytomas: a study with long-term follow-up. Br J Cancer 69: 586-591, 1994
30. Montine TJ, Bruner JM, Vandersteenhoven JJ, Dodge RK, Burger PC: Prognostic significance of p53 immunoreactivity in adult patients with supratentorial fibrillary astrocytic neoplasms. Diagn Mol Pathol 3 (4): 240-245, 1994
31. Nelson JS, Tsukuda Y, Schoenfeld D, Fulling K, Lamarche J, Peress N: Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer 52: 550-594, 1983
32. Bruner JM, Connelly J, Saya H: p53 protein immunostaining in routinely processed paraffin-embedded sections. Mod Pathol 6: 189-194, 1993
33. Kyritsis AP, Bondy ML, Xiao M, Berman EL, Cunningham JE, Lee PS, Levin VA, Saya H: Germline p53 gene mutations in subsets of glioma patients. J Natl Cancer Inst 86 (5): 344-349, 1994
34. Wu JK, Ye Z, Darras B: Frequency of p53 tumor suppressor gene mutations in human primary brain tumors. Neurosurgery 33: 824-831, 1993
35. Lang FF, Miller DC, Pisharody S, Koslow M, Newcomb EW: High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 9: 949-954, 1994
36. Kim B, Finn L, Martinez J, Campbell J, Pollack I, Bakker A, Swalsky PA, Finkelstein SD: Role of p53 gene alterations in pediatric high grade gliomas. Lab Invest 72: 143A, 1995
37. Forsyth PA, Shaw EG, Scheithauer BW, O'Fallon JR, Layton DD, Katzmann JA: Supratentorial pilocytic astrocytomas. Cancer 72: 1335-1342, 1993
38. Hayostek CJ, Shaw EG, Scheithauer BW, O'Fallon JR, Weiland TL, Schomberg PJ, Kelly PJ, Hu TC: Astrocytomas of the cerebellum. Cancer 72: 856-869, 1993
39. Rubio M-P, Von Deimling A, Yandell DW, Wiestler OD, Gusella JF, Louis DN: Accumulation of wild type p53 in human astrocytomas. Cancer Res 53: 3465-3467, 1993
40. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736-2739, 1993
41. Momand J, Zambetti GP, Olson DC, George DL, Levine AJ: The mdm-2 oncogene products forms a complex with p53 protein and inhibits p53-mediated trans-activation. Cell 69: 1237-1245, 1992
42. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ: Gain of function mutations in p53. Nature Genet 4: 42-46, 1993
43. Chin KV, Ueda K, Pastan I, Gottesman MM: Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255: 459-462, 1992